Regulatory T cells (T~reg~) are critical to maintain self-tolerance. They modulate the functions of different immune cells, thereby affecting a variety of conditions, including autoimmunity, cancer, allergy and inflammation[@R1], [@R2]. In addition, it is becoming increasingly clear that specialized T~reg~ cells in tissues are important to promote organ homeostasis, a function that was initially only attributed to tissue-resident macrophages[@R3]. In fat (visceral adipose tissue), T~reg~ cells support metabolic functions and express PPAR-γ, a master-regulator of adipocyte differentiation[@R3], [@R4], [@R5], and the IL-33R alpha chain (ST2)[@R6]. Other examples of tissue homeostasis promoted by specialized T~reg~ cells include injured skeletal muscles and lungs after influenza A infection[@R7], [@R8]. In both cases, T~reg~ cells present in damaged tissues produce amphiregulin (AREG), an epidermal growth factor receptor ligand important for tissue repair[@R7], [@R8].

The molecular mechanisms by which tissue-resident T~reg~ cells acquire and stabilize their 'tissular' program are poorly understood. Epigenetic modifications have been linked to establishing tissue-resident characteristics in macrophages[@R9], [@R10]. Similar mechanisms could be important to shape the tissue identity of T~reg~ cells.

Our methylome analysis revealed 11,000 differential methylated regions (DMRs) associated with about 4,000 genes. Shared epigenetic profiles led to the identification of a common tissue T~reg~ population, characterized by the epigenetic reprogramming of parts of the T-helper 2 (T~H~2) pattern and production of the tissue regenerative factor AREG. Our data suggest that epigenetic events shape the characteristics and function of tissue T~reg~ cells.

Results {#S1}
=======

Identification of differentially methylated regions {#S2}
---------------------------------------------------

To investigate the tissue-specific program of T~reg~ cells, we performed low-input tagmentation-based whole-genome bisulfite sequencing (TWGBS) to decipher the DNA methylome of T~reg~ cells isolated from different tissues. Utilizing *Foxp3-*reporter mice, we isolated T~reg~ cells from abdominal fat depots, skin, liver and inguinal lymph nodes (LN), and included conventional CD4^+^ T cells (T~conv~) from LN as a control population ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}). Three independent replicates per sample were performed and robust data were obtained for all samples with reproducible replicates, with about 7x10^8^ total reads per group and an average 20-fold coverage for each CpG per population ([Supplementary Fig. 2a](#SD2){ref-type="supplementary-material"}). In pairwise comparisons, a strict definition of at least 30% difference in DNA methylation was chosen and revealed about 11,000 unique differentially methylated regions (DMRs) ([Fig. 1b, c](#F1){ref-type="fig"} and [Supplementary Fig. 2b](#SD2){ref-type="supplementary-material"}). The average length of a DMR was about 1 kilo base pairs (kb), and annotation with genomic features derived from Refseq illustrated that the majority of DMRs were located in intragenic regions (63%), whereas promoter and intergenic regions comprised only 9% and 28%, respectively ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 2c,d](#SD2){ref-type="supplementary-material"}). We observed a peak of DMRs located immediately downstream of transcription start sites (TSS) ([Fig. 1d](#F1){ref-type="fig"}). Principal component analysis (PCA) showed that the methylation patterns of fat and skin T~reg~ were more similar to each other and rather distinct from LN T~reg~ and T~conv~ ([Fig. 1b, e](#F1){ref-type="fig"}). These results indicate that T~reg~ cells in tissues have a distinguishable methylation pattern.

RNA transcriptome analysis supports DNA methylation pattern {#S3}
-----------------------------------------------------------

We performed RNA sequencing (RNAseq) of T~reg~ cells and T~conv~ cells from tissues. The RNA transcriptome analysis revealed substantial gene expression differences between T~reg~ cells from tissues and LN. 3,072 and 4,698 genes were differentially expressed between fat or skin and LN T~reg~ cells, respectively. The comparison between fat and skin-resident T~reg~ cells showed 552 genes to be differentially expressed ([Fig. 2a](#F2){ref-type="fig"}). Unsupervised hierarchical clustering of the RNAseq data confirmed this notion and grouped fat and skin T~reg~ cells close together, whereas liver T~reg~ located closer to LN T~reg~ cells ([Fig. 2b](#F2){ref-type="fig"}). Hierarchical clustering of DMR methylation data resulted in a very similar grouping, suggesting that gene expression and DNA methylation patterns are interconnected ([Fig. 2c](#F2){ref-type="fig"}). Indeed, integrated analysis of both datasets showed a negative correlation of gene expression and DMR methylation (median -0.303) ([Fig. 2d](#F2){ref-type="fig"}), indicating that, in many cases, hypomethylation of a DMR correlated with the expression of the corresponding gene and vice versa. Such a correlation has been observed in similar studies[@R11].

T~reg~ cell-specific epigenetic signature {#S4}
-----------------------------------------

Methylation-based analyses of candidate regions have previously helped distinguish T~reg~ from T~conv~ cells. The most prominent example is a T~reg~-specific demethylated region in the *Foxp3* gene, located in the first intron and termed conserved non-coding sequence 2 (CNS2)[@R1], [@R12]. This analysis has been extended by using methylated DNA immunoprecipitation (MeDIP) to analyze differences between T~reg~ and T~conv~ cells from lymphatic organs[@R13]. That study identified a T~reg~ cell-specific CpG hypomethylation pattern that was established in the thymus and included, in addition to *Foxp3,* other T~reg~ signature genes[@R13]. Since our data set included T~reg~ and T~conv~ cells from LN, we first focused our analysis on this signature established in the thymus. Pairwise comparison between LN T~reg~ and T~conv~ cells revealed 339 DMRs ([Fig. 1c](#F1){ref-type="fig"}). When plotting the mean methylation difference (LN T~reg~ -- LN T~conv~) of promoter and intragenically located DMRs against RNA expression data of the corresponding genes, we identified a clear anti-correlation of demethylation being associated with increased gene expression, and gain of methylation with gene repression ([Fig. 3a](#F3){ref-type="fig"}). Our data confirmed T~reg~-specific hypomethylation at sites described in the earlier study[@R13], e.g. at *Ctla4, Ikzf2, Ikzf4,* and *Il2ra* ([Fig. 3b](#F3){ref-type="fig"}), while we also identified several novel hypomethylated sites linked to genes such as *Ccr6*, *Cish* and *Ift80*. Furthermore, we identified previously unappreciated hypermethylated regions in genes that were underrepresented in T~reg~ cells, such as *Itk, Satb1, Cox10, Fam78a* and *Tgfbr2* ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}).

Since TWGBS allows resolution at a single CpG level, we used this to study the *Foxp3* gene. The T~reg~-specific demethylation of *Foxp3* went far beyond the CNS2 region initially described[@R12], and spanned the entire first intron. Starting from exon 2, the remaining gene was methylated in T~reg~ cells ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 4](#SD2){ref-type="supplementary-material"}). To verify our whole-genome sequencing data with a complementary method, we selected several regions in the *Foxp3* gene and performed PCR-based amplification of bisulfite converted DNA, followed by sequencing of these amplicons ([Fig. 3d-f](#F3){ref-type="fig"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The amplicon sequencing data confirmed and validated the whole-genome methylation data and, additionally, established that demethylation of the entire intron 1, as well as an upstream region 1, could occur during differentiation of T~reg~ cells in the thymus ([Fig. 3d](#F3){ref-type="fig"} and [Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}). Furthermore, this *Foxp3* pattern was shown to be present in naive T~reg~ cells, but not in *in vitro* transforming growth factor-β (TGF-β)-induced (iT~reg~) cells ([Fig. 3e](#F3){ref-type="fig"} and [Supplementary Fig. 6](#SD2){ref-type="supplementary-material"}). In addition, methylation at the *Foxp3* gene was not responsible for differences in *Foxp3* expression levels ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}).

To further investigate the universality of this T~reg~-specific methylation signature, we isolated peripherally-induced (pT~reg~) and thymus-derived T~reg~ cells (tT~reg~). pT~reg~ cells are characterized by the expression of the transcription factor RORγt and do not express the transcription factor HELIOS (*Ikzf2*), whereas tT~reg~ cells do not express RORγt, but express HELIOS[@R14]. We sorted both populations from the spleen and performed PCR-based amplification of bisulfite converted DNA for regions in *Ctla4, Ikzf2, Il2ra* and *Foxp3.* Although *Ctla4, Il2ra* and *Foxp3* were uniformly hypomethylated in both T~reg~ populations, *Ikzf2* was completely methylated in pT~reg~ cells, identifying differences in methylation of *Ikzf2* as an epigenetic mark to differentiate between pT~reg~ and tT~reg~ cells ([Fig. 3g](#F3){ref-type="fig"} and [Supplementary Fig. 8](#SD2){ref-type="supplementary-material"}).

In summary, TWGBS is a powerful method to study T~reg~ cell-specific methylation differences at a single CpG level.

Epigenetic landscape of tissue T~reg~ cells {#S5}
-------------------------------------------

While pairwise comparison between LN T~reg~ and T~conv~ cells identified 339 DMRs, the number of DMRs between fat or skin T~reg~ versus LN T~reg~ was about 5-fold larger (1,593 and 1,645 DMRs, respectively) ([Fig. 1c](#F1){ref-type="fig"}). Many of the DMRs were shared between fat versus LN and skin versus LN T~reg~ cells, indicating either common effector/memory or specific tissue T~reg~ programs ([Fig. 4a](#F4){ref-type="fig"}). We extracted 106 genes that showed differential methylation and corresponding gene expression changes in both comparisons ([Fig. 4b](#F4){ref-type="fig"}). To differentiate between common effector/memory and tissue T~reg~ programs, we compared this signature with RNAseq data from T~conv~ cells isolated from the same peripheral tissue ([Fig. 4b](#F4){ref-type="fig"} and [Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}). Although individual genes of this list could be identified as common effector/memory related, e.g. *Foxp1* or *Lef1*, the majority of the 106 genes were part of tissue T~reg~ programs and not just common effector/memory related. Pairwise comparisons of T~reg~ and CD4 non-T~reg~ cells from the same tissue revealed that the signature of 106 genes was highly significantly biased towards tissue T~reg~ cells ([Supplementary Fig. 9b](#SD2){ref-type="supplementary-material"}).

In many cases, methylation at the promoter sites was similar between the groups, but started to be differential just after the TSS in the first intron, as observed in the *Foxp3* gene ([Fig. 4c](#F4){ref-type="fig"} and [Supplementary Fig. 10](#SD2){ref-type="supplementary-material"}). For selected genes, we confirmed differential expression at the protein level via flow cytometry ([Fig. 5a](#F5){ref-type="fig"}). For example, *Klrg1* displayed hypomethylation in tissue T~reg~ cells, and was expressed by more than 80% of T~reg~ cells in the skin and fat, but only by about 10% of T~reg~ cells from LN. Hypomethylation and expression of TIGIT and ST2 behaved similarly. The strong changes in protein expression observed for TIGIT, KLRG1 and ST2, were not found in T~conv~ cells isolated from skin and fat ([Fig. 5a](#F5){ref-type="fig"}).

In addition to shared characteristics, we were also interested in differences between tissue T~reg~ cells ([Fig. 5b](#F5){ref-type="fig"}). The comparison between fat and skin T~reg~ cells revealed that the key transcription factor of visceral adipose tissue T~reg~ differentiation, *Pparg,* was hypomethylated in fat T~reg~ cells and, concomitantly, the gene was also highly expressed ([Fig. 5c](#F5){ref-type="fig"}). On the other hand, skin T~reg~ cells had several specifically hypomethylated gene loci, including *Ahr, Icos, Itgae* (CD103) and *Gpr55*, and all corresponding genes were overexpressed in skin T~reg~ cells ([Fig. 5b, d, e](#F5){ref-type="fig"} and [Supplementary Fig. 11](#SD2){ref-type="supplementary-material"}).

Overall, these results showed that the epigenetic landscape of fat and skin T~reg~ cells shared many characteristics.

Epigenetic reprogramming of T~H~2-associated loci {#S6}
-------------------------------------------------

To further delineate common principles of tissue T~reg~ cells, a gene ontology (GO) analysis of the 106 genes with differential methylation and expression patterns ([Fig. 4b](#F4){ref-type="fig"}) was performed. At the top of the list were GO terms describing T cell differentiation ([Fig. 6a](#F6){ref-type="fig"}). Four transcription factors were particularly enriched in these lists, namely *Gata3, Irf4, Rora,* and *Batf,* all of which were hypomethylated and overexpressed in fat and skin T~reg~ cells ([Fig. 6b](#F6){ref-type="fig"} and [Supplementary Fig. 12](#SD2){ref-type="supplementary-material"}). GATA-3 and IRF4 are key transcription factors determining the T~H~2 fate decision of CD4^+^ T cells[@R15]. To probe whether fat and skin T~reg~ cells show a generalized type-2 profile, a selected list of diagnostic T~H~2 probes[@R16] was used to plot skin T~reg~ versus LN T~reg~ and fat T~reg~ versus LN T~reg~ cells. In both cases, T~H~2 overexpressed as well as T~H~2 underrepresented genes were significantly biased towards the respective tissue T~reg~ site, indicating a type-2 polarization ([Fig. 6c](#F6){ref-type="fig"}). For example, *Il1rl1* (encoding for ST2) and *Il10,* both associated with type-2 conditions[@R15], [@R17], were hypomethylated in tissue T~reg~ cells. *Il10* displayed two hypomethylation regions, one about 9 kb upstream of the promoter and a second intragenic region. The upstream region falls into a previously described DNaseI hypersensitive site of the *Il10 locus* in T~H~2 cells[@R18]. The *Il1rl1* (ST2) gene was hypomethylated in the first intron, and about 90% of the fat T~reg~ and 60% of skin T~reg~ cells expressed ST2, as compared to less than 10% in the spleen counterpart ([Fig. 6d](#F6){ref-type="fig"} and [Supplementary Fig. 13](#SD2){ref-type="supplementary-material"}). If tissue T~reg~ cells from fat and skin were type-2 biased, it should be possible to recapitulate parts of their phenotype by treating lymphoid T~reg~ cells with IL-4. Indeed, IL-4 treatment of lymphoid T~reg~ cells strongly induced the expression of *Gata3, Irf4, Il1rl1* and *Il10,* but repressed *Ms4a4b*, a T~H~1-associated gene, underrepresented in tissue T~reg~ cells, in a dose-dependent manner ([Fig. 6e](#F6){ref-type="fig"} and [Supplementary Fig. 14](#SD2){ref-type="supplementary-material"}).

Demethylation at CG sites can allow transcription factors (TF) to modulate gene transcription[@R19]. We studied the TF binding motifs that were enriched in hypomethylated DMRs found in fat and skin T~reg~ cells, and represented in cluster 2 ([Fig. 6f](#F6){ref-type="fig"}; upper panel). Among the twelve TF with an enrichment of their binding motif in cluster 2, eleven were also overexpressed in fat and skin T~reg~ cells, including *Rora*, *Batf*, and different members of the *Jun* and *Fos* family ([Fig. 6f](#F6){ref-type="fig"}; lower panel). The BATF-JUN complex promotes DNA binding of the transcription factor IRF4 and the IRF4--JUN--BATF heterotrimeric complex was shown to be critical for IRF4-mediated transcription in T cells[@R20], thereby, the complex may reinforce type-2 polarization.

Characterization of tissue ST2^+^ T~reg~ cells {#S7}
----------------------------------------------

We called the here identified T~H~2-biased subset of T~reg~ cells, expressing ST2 and dominating the T~reg~ population in fat and skin tissue, 'tissue T~reg~ ST2 cells' (tisT~reg~ST2). They are characterized by epigenetic and gene expression differences of 106 genes ([Fig. 4b](#F4){ref-type="fig"}), such as *Gata3, Irf4, Batf, Rora, Maf, Il1rl1, Il10, CD200r1, Tigit,* and *Klrg1*. Fat and skin T~reg~ cells showed demethylation and overexpression of *Maf* (*c-maf*), an originally described T~H~2 cell-associated TF able to bind to the *Il10* promoter and induce *Il10* transcription[@R18]. In addition, one of the fundamental characteristics of tisT~reg~ST2 cells is the expression of AREG, a T~H~2-associated epidermal growth factor receptor ligand[@R21]. The *Areg* gene locus harbored two hypomethylated regions upstream of the promoter in fat and skin T~reg~ cells ([Supplementary Fig. 15](#SD2){ref-type="supplementary-material"}).

Since expression of ST2, KLRG1, TIGIT and GATA-3 characterized tisT~reg~ST2 cells in fat and skin, we used these markers to screen a number of organs for the presence of this cell type. While fat and skin had the highest fraction of tisT~reg~ST2 within the Foxp3-positive T~reg~ compartment (about 80-90% and 50-60%, respectively), other peripheral organs such as lung, bone marrow and liver contained 10-20% of them, and lymphoid organs had the lowest fraction with less than 5%, ([Fig. 7a, b](#F7){ref-type="fig"}). We could not detect a ST2^+^KLRG1^+^ population in the T~conv~ compartment in skin, liver, blood, BM, lung, and only a minor (\< 5%) population in fat tissue ([Supplementary Fig. 16a](#SD2){ref-type="supplementary-material"}). While tisT~reg~ST2 cells from the different organs similarly expressed, for example, high levels of GATA-3, the corresponding T~conv~ population did not resemble tisT~reg~ST2 characteristics ([Fig. 7a](#F7){ref-type="fig"} and [Supplementary Fig. 9b, 16b, c](#SD2){ref-type="supplementary-material"}).

To further study the influence of T cell receptor (TCR) signaling and activation on the tisT~reg~ST2 population within the T~reg~ compartment in tissues, we separated T~reg~ cells based on different expression levels of CD44, an effector/memory marker. The tisT~reg~ST2 population was almost exclusively located in the CD44-high effector/memory compartment ([Supplementary Fig. 17a](#SD2){ref-type="supplementary-material"}), which is in accordance with previous literature of tissue-resident T~reg~ cells being of effector/memory phenotype[@R22]. Since high expression of CD44 in tisT~reg~ST2 suggested a previous activation event via TCR-signaling, we analyzed this population in *Nr4a1* (which encodes Nur77)-GFP reporter mice, where TCR signal strength is measured by reporter activity[@R23]. Therefore, we subdivided the T~reg~ pool in GFP-high, GFP-intermediate and GFP-negative fractions to study whether the presence of tisT~reg~ST2 cells depends on ongoing TCR signaling. Although the frequency of tisT~reg~ST2 was much lower in the lymphatic organs as compared to the fat tissue (1-2% vs. 90%, respectively), the per-organ fraction of tisT~reg~ST2 was not influenced whether current TCR-signaling was on or off ([Supplementary Fig. 17b](#SD2){ref-type="supplementary-material"}).

Next, we wanted to elaborate whether tisT~reg~ST2 cells could be part of the induced T~reg~ population in tissues. Previous publications have described that the colon harbors two distinct T~reg~ populations, pT~reg~ and tT~reg~ cells[@R14]. Unlike HELIOS^+^RORγt^--^ tT~reg~ cells, pT~reg~ cells are induced by commensal bacteria in the colon. TisT~reg~ST2 cells were only present in the tT~reg~ population of the colon, where they represented about 40% of all tT~reg~ cells. The RORγt-positive pT~reg~ compartments in the colon and spleen were completely devoid of tisT~reg~ST2 cells ([Fig. 7c](#F7){ref-type="fig"} and [Supplementary Fig. 18a](#SD2){ref-type="supplementary-material"}). Importantly, tisT~reg~ST2 cells located in the colon expressed higher levels of GATA-3 compared to pT~reg~ and 'non-tisT~reg~ST2' tT~reg~ cells in the same tissue ([Supplementary Fig. 18b](#SD2){ref-type="supplementary-material"}). In summary, tisT~reg~ST2 cells can be identified in virtually every peripheral tissue.

TisT~reg~ST2 in the spleen {#S8}
--------------------------

We investigated whether the small population of tisT~reg~ST2 found in lymphatic organs resembled the tisT~reg~ST2 pattern found in peripheral tissues. One of the important characteristics that we found in tisT~reg~ST2 cells in skin and fat was the production of AREG and IL-10. To this end, we stimulated fat and spleen tisT~reg~ST2 cells. About 80% of KLRG1^+^ST2^+^ tisT~reg~ST2 cells from spleen produced AREG and showed elevated levels of IL-10 when compared to spleen KLRG1^--^ST2^--^ T~reg~ cells, and thereby demonstrated a very similar effector profile comparable to tisT~reg~ST2 cells isolated from fat tissue ([Fig. 7d](#F7){ref-type="fig"} and [Supplementary Fig. 19a, b](#SD2){ref-type="supplementary-material"}). CD8^+^ T cells and T~conv~ did not produce AREG and IL-10 under the same conditions ([Supplementary Fig. 19a](#SD2){ref-type="supplementary-material"}). To further validate the similarities, we sorted the tisT~reg~ST2 population from spleen and analyzed the characteristic tisT~reg~ST2 profile, including additional genes that showed epigenetic changes in fat and skin T~reg~ populations such as lamin A (*Lmna*) or oxysterol binding protein like 3 (*Osbpl3*). All analyzed genes were differentially expressed in the tisT~reg~ST2 fraction from spleen compared to the global splenic T~reg~ pool, including *Gata3, Rora* and *Irf4,* matching the profile of tisT~reg~ST2 cells ([Fig. 7e](#F7){ref-type="fig"}). Especially the effector molecules *Il10* and *Areg* were highly overrepresented with 65-fold and 16-fold difference, respectively, validating our functional protein expression data. To investigate whether the tisT~reg~ST2 characteristic methylation changes could also be observed in the spleen counterpart, we sequenced PCR-based amplicons of bisulfite converted DNA based on DMRs identified in our whole-genome approach. Genes specifically demethylated in fat and skin tisT~reg~ST2 cells, such as *Gata3* or *Klrg1*, were also hypomethylated in splenic tisT~reg~ST2 cells, but not splenic Klrg1^--^ST2^--^ T~reg~ cells ([Fig. 7f](#F7){ref-type="fig"}).

To further dissect the tisT~reg~ST2 cells found in lymphoid organs, we first looked at individual marker expression. Virtually all T~reg~ cells in the skin expressed high levels of CD103, whereas less than 5% of fat-resident tisT~reg~ST2 cells expressed this marker Analysis of tisT~reg~ST2 cells from spleen showed that about 40% express CD103, indicating a heterogeneity of the tisT~reg~ST2 population in this organ ([Supplementary Fig. 19c](#SD2){ref-type="supplementary-material"}). Induction of PPAR-γ in the fat tisT~reg~ST2 population represented an additional functional tissue-based adaptation ([Fig. 5c](#F5){ref-type="fig"} and [Supplementary Fig. 20](#SD2){ref-type="supplementary-material"}), comparable to demethylation and expression of the cannabinoid receptor gene *Gpr55* in skin T~reg~ cells ([Fig. 5d](#F5){ref-type="fig"} and [Supplementary Fig. 20](#SD2){ref-type="supplementary-material"}). When looking at the markers *Pparg* and *Gpr55,* which indicate tissue-restricted adaption of the tisT~reg~ST2 pool in fat and skin, we found both to be highly over-represented in the spleen tisT~reg~ST2 population (\>30-fold) ([Fig. 7g](#F7){ref-type="fig"}). To extend this analysis, we performed single cell RNA sequencing (scRNAseq) of tisT~reg~ST2 cells isolated from spleen. As expected, all single cells expressed *Helios, Gata3* and *Klrg1*. In contrast to this, genes that were biased towards the skin-resident tisT~reg~ST2 population, like *Itgae* (CD103), *Ahr* or *Gpr55* were only expressed in a fraction of individual cells, indicating the presence of subgroups of tisT~reg~ST2 in the spleen, probably representing individual tissue characteristics ([Fig. 7h](#F7){ref-type="fig"}). This suggests that fat and skin-resident T~reg~ cells contain a recirculating fraction present in the lymphatic tisT~reg~ST2 pool.

TisT~reg~ST2 are distinct {#S9}
-------------------------

To analyze whether tisT~reg~ST2 are a distinct differentiation state of T~reg~ cells, we first analyzed the presence of these cells over time. Our data showed that the fraction of tisT~reg~ST2 cells among T~reg~ cells in different tissues was stable over a time period of 5 to 25 weeks of age, indicating homeostasis of the tisT~reg~ST2 compartment within tissues ([Fig. 8a](#F8){ref-type="fig"} and [Supplementary Fig. 21a, b](#SD2){ref-type="supplementary-material"}). To understand the origin of tisT~reg~ST2 cells, we studied whether lymphoid organ-derived, tisT~reg~ST2-depleted T~reg~ cells could be the precursor of tisT~reg~ST2 cells found in tissues. To generate space in the T~reg~ compartment, host T~reg~ cells were depleted by injecting diphtheria toxin into *Foxp3*-DTR mice. Congenically marked KLRG1^--^ST2^--^ T~reg~ cells were injected and skin and fat tissue was analyzed for the presence of tisT~reg~ST2 cells after 10 days. These experiments showed that lymphoid organ T~reg~ cells have the ability to seed the peripheral tissues and differentiate into tisT~reg~ST2 cells ([Fig. 8b](#F8){ref-type="fig"}).

To study the stability of already differentiated tisT~reg~ST2 cells, we cultured fat-derived tisT~reg~ST2 under well-defined conditions with anti-CD3+CD28 beads and IL-2 for six days *in vitro*. TisT~reg~ST2 cells showed a very stable expression pattern of characteristic markers such as *Il1rl1, Pparg, Osbpl3, Batf, Tigit, Gata3,* and *Klrg1* comparable to freshly isolated tisT~reg~ST2 from fat. In parallel, cultivated 'non-tisT~reg~ST2' T~reg~ cells did not upregulate these characteristic genes, indicating that expression of these genes is not a mere function of T~reg~ activation and that the tisT~reg~ST2 program is not a temporary state, but a stable program ([Fig. 8c](#F8){ref-type="fig"}).

In order to identify an essential transcription regulator for tisT~reg~ST2 cells, we focused on BATF. As described earlier, our data showed that *Batf* is over-expressed in tisT~reg~ST2 cells, its gene locus is heavily hypomethylated in tissue T~reg~ cells from fat and skin, and we identified an enrichment of BATF DNA binding motifs in regions of genes that were specifically hypomethylated in tissue T~reg~ cells. Indeed, BATF deficient mice showed severely reduced numbers of tisT~reg~ST2 in all organs analyzed, including skin, fat, lung, bone marrow, LN and spleen, while numbers of other T~reg~ cells in the same tissues were not reduced. These data show that BATF is an essential transcriptional regulator of tisT~reg~ST2 cells ([Fig. 8d](#F8){ref-type="fig"}).

As tisT~reg~ST2 cells are characterized by the expression of ST2, we wanted to understand if IL-33 could act as a growth factor amplifying the tisT~reg~ST2 pool *in-vivo*. Administration of recombinant IL-33 substantially expanded the tisT~reg~ST2 population in all organs tested. Numbers of tisT~reg~ST2 cells were increased by 10-fold in fat, 5-fold in skin, 13-fold in liver, and 60-fold in lung tissue ([Fig. 8e](#F8){ref-type="fig"}). This expansion did not change the identity, as GATA-3 was still over-expressed in expanded cells as compared to 'non-tisT~reg~ST2' T~reg~ cells isolated from the same organs ([Supplementary Fig. 21c](#SD2){ref-type="supplementary-material"}). Collectively, these data showed that tisT~reg~ST2 cells are a distinct state. They require the transcription factor BATF, and can be expanded via IL-33 signaling *in situ*.

Discussion {#S10}
==========

The present study provides evidence that tissue T~reg~ cells undergo extensive epigenetic reprogramming. Changes in the methylome can be used to determine the underlying functional programs. The similarities in the epigenetic landscape between fat- and skin-resident T~reg~ cells allowed us to identify a common tissue T~reg~ population, characterized by the expression of KLRG1 and ST2, a T~H~2-like program, and the production of tissue regenerative factors.

Classically, T~reg~ cells were viewed as regulators of other immune cells. With the characterization of fat T~reg~ cells, this notion has been extended to a second critical function, supporting organ homeostasis[@R3]. In visceral adipose tissue, about 80-90% of T~reg~ cells represent the here described tisT~reg~ST2 phenotype. In skin, this number was somewhat lower at about 50-60% of T~reg~ cells, and in lung and liver between 10-20%. These findings explain why fat and skin-resident T~reg~ cells shared a closer relation in the DNA methylome analysis as compared to liver T~reg~ cells. It is intriguing that this T~H~2-biased tisT~reg~ST2 subset is present in virtually every organ. ST2, as well as the transcription factors BATF and IRF4, were shown to be required for fat T~reg~ cell differentiation[@R6]. Based on our data, we could show that BATF and IL-33 are not just important for fat T~reg~ cells, but for tisT~reg~ST2 in all tissues, extending the perspective from an adipose centered view to a global one.

Our data also show that tissue T~reg~ cells integrate epigenetic changes from multiple differentiation steps. The first specific epigenetic reprogramming occurs during thymic differentiation and stabilizes the universal T~reg~ identity[@R13]. The second line of epigenetic modifications solidifies the functional 'tisT~reg~ST2' specialization via selective hypomethylation of a signature that includes more than 100 genes. Thereby, the tisT~reg~ST2 population acquires a unique reprogramming landscape. On top of this tisT~reg~ST2 specialization program, we find tissue-specific epigenetic reprogramming. In the fat T~reg~ population, we identified, among others, methylation differences in the *Pparg* gene. In addition, skin T~reg~ cells revealed several interesting epigenetic differences, where *Ahr* and *Gpr55* could be of specific relevance. Ahr signaling is important for immune cells and their function at barrier organs such as the skin[@R24]. Grp55, as a cannabinoid receptor, is associated with algesia linked to inflammatory and neuropathic pain, and could enable nociception by skin T~reg~ cells in an organ with a strong pain perception[@R25], [@R26].

Where does the epigenetic reprogramming take place? Are most organs independently able to induce the common tisT~reg~ST2 program, and, in addition, add organ specific flavors? Alternatively, one or very few organs could induce the tisT~reg~ST2 reprogramming and, by circulation, cells reach the individual tissues where they further specialize. In the latter, the fat tissue could be such a candidate as the vast majority of T~reg~ cells in this tissue are tisT~reg~ST2 reprogrammed. However, parabiosis experiments detected only a low degree of chimerism in the fat tissue T~reg~ compartment, indicating little exchange of tissue T~reg~ cells via the circulation[@R27]. It is also possible that tisT~reg~ST2 cells found in spleen or LN represent a backup population that can quickly be recruited to support distressed organ homeostasis. In addition, it is very unlikely that local conversion from T~conv~ into T~reg~ is responsible since our data show that tisT~reg~ST2 are only present in the tT~reg~, but not pT~reg~ fraction, and are demethylated at the *Ikzf2* locus.

TisT~reg~ST2 do not express the T~H~2-associated cytokines IL-4 and IL-13, but express IL-10 and AREG. *Areg* expression could presumably be induced by ST2 signaling, and was shown to be important for tissue repair in the lung[@R8]. The tisT~reg~ST2 population could therefore represent the prototype of tissue-repair prone T~reg~ cells mediating tissue homeostasis by using the tissue regenerative factor AREG. This could have clinical implications in the adoptive transfer of T~reg~ cells to treat autoimmune and graft versus host diseases[@R28]. Deliberate type-2 conditioning by IL-4 and IL-33 during the *in vitro* expansion of blood-derived T~reg~ cells might amplify their therapeutic potential, especially in respect to supporting tissue repair functions. Indeed, ST2-dependent protective T~reg~ functions could be demonstrated in the colon and adipose tissue[@R6], [@R29].

As *Foxp3* demethylation is used as a diagnostic marker to detect T~reg~ cells[@R12], [@R30], peripheral reprogramming events can be used to study the functional capacity of T~reg~ cells. We identified thousands of DMRs with single CpG resolution, characterizing the universal T~reg~ identity and the peripheral reprogramming. These differences will allow the design of diagnostic probes for amplicon-based sequencing to follow the origin and cell fate of T~reg~ cells in various pathological conditions. Indeed, the here described difference in methylation of *Ikzf2* between tT~reg~ and RORγt-positive pT~reg~ cells is such an example. Analyzing the epigenetic landscape is more than a complementary approach to describe T~reg~ cells; it will help to define T~reg~ cell identities and the permanent underlying molecular programs.

Data availability Statement {#S11}
===========================

The source data are deposited as Fastq files from all TWGBS, RNA-Seq, and single-cell RNA-Seq in the European Nucleotide Archive (ENA) with the accession code PRJEB14591 (<http://www.ebi.ac.uk/ena/data/view/PRJEB14591>).

Online Methods {#S12}
==============

Mice {#S13}
----

Wildtype C57BL/6, congenic B6.SJL-Ptprc^a^Pepc^b^/BoyCrl (CD45.1^+^), congenic B6.PL-Thy1^a^/CyJ (CD90.1^+^), and *Nr4a1*-GFP (C57BL/6-Tg(Nr4a1-eGFP/cre)820Khog/J; Jackson Stock Number: 016617)[@R23] mice were obtained from Charles River Breeding Laboratories (Wilmington, MA, USA) or the Jackson Laboratory (Bar Harbor, ME, USA). B6N.129(Cg)-Foxp3^tm3Ayr^ mice (Foxp3.IRES-DTR/GFP)[@R31] were bred to CD45.1^+^ or CD90.1^+^ mice in the animal facility of the German Cancer Research Center (DKFZ). B6N.129(Cg)-Foxp3^tm3Ayr^ and B6.129(Cg)-Foxp3^tm4(YFP/cre)Ayr^/J, Jackson (Foxp3.IRES-YFP/Cre)[@R32] were used to sort YFP or GFP positive T~reg~ cells.

All animals used in this study were male and between 15 and 30 weeks old, unless otherwise indicated. Animals were housed under specific pathogen-free conditions at the DKFZ animal care facility, and the governmental committee for animal experimentation (Regierungspräsidium Karlsruhe, Germany) approved all experiments involving animals.

Tissue digestion for flow sorting of cells {#S14}
------------------------------------------

For cell isolation, we used *Foxp3*^GFP^ or *Foxp3*^YFP^ reporter mice (Foxp3.IRES-DTR/GFP or Foxp3.IRES-YFP/Cre). T cells were extracted from gonadal visceral adipose tissue (called fat in the study), skin, liver, and inguinal lymph nodes. For lymph nodes, single-cell suspensions were established and red blood cells were lysed. Epididymal visceral abdominal tissue was first mechanically dissected followed by digestion with a buffer containing collagenase II (1 mg/mL), BSA (20 mg/mL) and DNAse (20 µg/mL) for 45 minutes at 37°C in a slow shaking waterbath. Afterwards, the cell suspension was shortly incubated with 0.5 Mol EDTA-H~2~O, pelleted and further filtered. To isolate cells from skin tissue, back skin area of sacrificed skin was depilated by shaving and hair removal cream, followed by mechanically dissection and digest using a buffer containing collagenase IV (4 mg/mL), FCS (2% vol/vol), and DNAse (10 µg/mL) for 45 minutes at 37°C in a slow shaking waterbath, followed by filtration steps. Liver tissue cells were isolated from perfused animals, mechanically dissected and treated with digestion buffer containing collagenase II (1 mg/mL), BSA (5 mg/mL), and DNAse (20 µg/mL) for 45 minutes at 37°C in a slow-shaking waterbath followed by a Percoll gradient centrifugation step and filtrations. Cells from lung were isolated from perfused animals following a digestion step similar to fat cells (collagenase II (1 mg/mL), BSA (20 mg/mL) and DNAse (20 µg/mL)).

After purification, cells were filtered through a 70µM filter mesh and either stained for flow cytometry-based isolation of target cells or pre-enriched with anti-CD25 magnetic beads followed by column-based isolation. Cells were stained with antibodies as indicated in the next paragraph. Live/dead cell exclusion was performed with a fixable live/dead stain.

Flow sorting and DNA/RNA purification {#S15}
-------------------------------------

Stained cells were twice sorted, first "pre-sorted" with moderate purity settings on a BD ARIA II or III cell-sorting machine (4-way sort, "enrich mode") into flow buffer. Then, cells were re-acquired and sorted again with high purity settings (4-way sort, "4-way purity mode") directly into either DNA or RNA lysis buffer. Aliquots were sorted into flow buffer for post-sort purity controls, as illustrated in [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}. T~reg~ cells from tissues were defined as CD3^+^CD4^+^CD8^--^CD45^+^CD25^+^Foxp3(GFP)^+^ population, while T~conv~ cells were sorted as CD3^+^CD4^+^CD8^--^CD45^+^Foxp3(GFP)^--^ or as CD3^+^CD4^+^CD8^--^CD19^--^CD45^+^CD90.1^+^Foxp3(GFP)^--^ population. Spleen pT~reg~ were defined as CD4^+^CD8^--^CD19^--^MHCII^--^CD25^+^Foxp3(GFP)^+^HELIOS^--^RORγt^+^, while spleen tT~reg~ were defined as CD4^+^CD8^--^CD19^--^MHCII^--^CD25^+^Foxp3(GFP)^+^HELIOS^+^RORγt^--^. TisT~reg~ST2 cells were defined as CD3^+^CD4^+^CD8^--^CD45^+^CD25^+^Foxp3(GFP)^+^KLRG1^+^ST2^+^ population. In the thymus, double negative 1 (DN1) thymocytes were sorted as CD4^--^CD8^--^CD25^--^CD44^+^, early thymic T~reg~ precursors as CD4^+^CD8^--^TCRb^+^CD69^+^CD25^--^Foxp3(GFP)^--^, late thymic T~reg~ precursors as CD4^+^CD8^--^TCRb^+^ CD69^+^CD25^+^Foxp3(GFP)^--^, and mature thymus T~reg~ cells as CD4^+^CD8^--^TCRb^+^CD69^--^CD25^+^Foxp3(GFP)^+^. From spleen and lymph nodes, we isolated CD44-positive T~reg~ cells (CD4^+^CD8^--^CD44^+^CD25^+^CD25^+^ Foxp3(GFP)^+^), CD44-positive T~conv~ cells (CD4^+^CD8^--^CD44^+^CD25^--^ Foxp3(GFP)^--^), naive T~reg~ cells (CD4^+^CD8^--^CD44^--^CD25^+^ Foxp3(GFP)^+^), naive T~conv~ cells (CD4^+^CD8^--^CD44^--^CD25^--^Foxp3(GFP)^--^), *in vitro* induced T~reg~ cells (CD4^+^CD8^--^CD25^+^Foxp3(GFP)^+^) and *in vitro* activated T~conv~ cells (CD4^+^CD8^--^CD25^+^Foxp3(GFP)^--^). In addition, we sorted Foxp3^high^, Foxp3^intermediate^, and Foxp3^low^ expressing T~reg~ cells (CD3^+^CD4^+^CD8^--^CD19^--^CD25^+^Foxp3(GFP)^high/int/low^), CD25^negative^ Foxp3-expressing cells (CD3^+^CD4^+^CD8^--^CD19^--^CD25^--^Foxp3(GFP)^+^) and T~conv~ cells (CD3^+^CD4^+^CD8^--^CD19^--^CD25^--^Foxp3(GFP)^-^) from spleen and lymph nodes. Genomic DNA was isolated using a gDNA Microprep Kit (Zymo Research) and concentrations were measured with a Qubit® fluorometer. RNA was isolated with the RNEasy mini kit (Quiagen) and concentration was determined with a 2100 Bioanalyzer instrument (Agilent technologies).

Tagmentation-based whole genome bisulfite sequencing (TWGBS) {#S16}
------------------------------------------------------------

We applied TWGBS for very low input DNA amounts according to [@R33] with some modifications. Double stranded pre-adapters consisted of oligo Tn5MErev (\[phos\]CTGTCTCTTATACACATCT) and either methylated oligo Tn5mC-Apt1 (TcGTcGGcAGcGTcAGATGTGTATAAGAGAcAG) or methylated oligo Tn5mC-Apt2 (GTcTcGTGGGcTcGGAGATGTGTATAAGAGAcAG); the lower case c base indicates 5-methyl cytosine. Pre-adapters were combined at 1:1 ratio to generate a 10 µM load adapter mixture. The transposome was assembled by mixing 12 µL load adapter and 10µL Ez-Tn5 transposase (Epicentre). About 10 ng genomic DNA and 5pg unmethylated λ DNA were used for tagmentation with 1 µl transposome. Tagmented DNA was purified with AmPure beads (Beckman Coulter) and repaired with Bst DNA polymerase (NEB) and 5mC-dNTP mix (Zymo). After a further bead purification, the DNA was bisulfite-converted with the EZ DNA methylation kit (Zymo) according to the manufacturer's instructions. From each converted DNA sample, four differently barcoded sequencing libraries were generated by PCR (95°C, 3 min; 12 cycles 95°C, 20 sec; 62°C, 15 sec; 72°C, 40 sec) using Kapa 2G Robust HotStart ReadyMix (Kapa Biosystems), SYBRGreen reagent (Life Technologies), primer Tn5mCP1 (AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTC) and barcoded Tn5mC reverse primers (CAAGCAGAAGACGGCATACGAGAT (- 8 bases barcode-) GTCTCGTGGGCTCGG). Library pools were 100bp paired-end sequenced using Illumina HiSeq 2000.

Ultra-low RNA Sequencing {#S17}
------------------------

cDNA was generated and amplified using 0.8 ng of total RNA and SMARTer Ultra Low Input RNA for Illumina Sequencing - HV (Clontech Laboratories, Inc.) according to the manufacturer's protocol. Then, sequencing libraries were prepared using the NEXT ChIP-Seq Library Prep Master Mix Set for Illumina (New England Biolabs) according to the manufacturer\'s instructions with the following modifications: The adapter-ligated double-stranded cDNA (10µl) was amplified using NEBNext Multiplex Oligos for Illumina (New England Biolabs, 25 µM primers), NEBNext High-Fidelity 2x PCR Master Mix (New England Biolabs) and 15 cycles of PCR. Final libraries were validated using Agilent 2100 Bioanalyzer (Agilent Technologies) and Qubit flourometer (Invitrogen), normalized and pooled in equimolar ratios. 50bp single-read sequencing was performed on the Illumina HiSeq 2000 v4 according to the manufacturer's protocol.

Read pair preprocessing of TWGBS data {#S18}
-------------------------------------

To determine whether read pairs originated from the original strand in the genome (C converted to T in read 1 and G converted to A in read 2 during bisulfite treatment) or the reverse complementary (G converted to A in read 1 and C converted to T in read 2), we performed the following preprocessing before the alignment: Since the Cs in CpG sites are mainly methylated thus unconverted, they were excluded from the analysis, i.e., CpG, TpG, GpC and GpT dinucleotides were masked. For each read in every read pair, we than calculated the base ratios T/C and A/G denoted as R1~T/C~, R1~A/G~ and R2~T/C~, R2~A/G~. We then compared these ratios between the first and second read in a read pair to determine if they are assigned in (R1-R2) or (R2-R1) order or cannot be assigned to any order. The following rules were applied: (1) Read pairs where the condition R1~T/C~ \> R2~T/C~ and R2~A/G~ \> R1~A/G~ held true, we assumed the read pair came from the original strand and assigned them the (R1-R2) read order. (2) Read pairs where the conditions R1~T/C~ \< R2~T/C~ and R2~A/G~ \< R1~A/G~ were met, we assumed the read pair came from the reverse complementary strand and read order (R2-R1) was assigned. (3) Read pairs that did not meet one of the conditions above were ambiguous thus disregarded from the analysis.

Mapping of whole-genome bisulfite sequencing data and methylation calling {#S19}
-------------------------------------------------------------------------

The TWGBS data were processed as described in [@R34]: The mm10 reference genome (GRCm38.73) was transformed *in silico* for both the top strand (C to T) and bottom strand (G to A) using MethylCtools[@R35]. Before alignment, adapter sequences were trimmed using SeqPrep (<https://github.com/jstjohn/SeqPrep>). The first read in each read pair was then C-to-T converted and the second read in the pair was G-to-A converted. The converted reads were aligned to a combined reference of the transformed top (C to T) and bottom (G to A) strands using BWA (bwa-0.6.2-tpx)[@R36] with default parameters, yet disabling the quality threshold for read trimming (-q) of 20 and the Smith-Waterman for the unmapped mate (-s). After alignment, reads were converted back to the original states, and reads mapped to the antisense strand of the respective reference were removed. Duplicate reads were marked, and the complexity determined using Picard MarkDuplicates (<http://picard.sourceforge.net/>). Reads with alignment scores less than 1 were filtered before subsequent analysis. Total genome coverage was calculated using the total number of bases aligned from uniquely mapped reads over the total number of mappable bases in the genome. At each cytosine position, reads that maintain the cytosine status were considered methylated, and the reads that have cytosine converted to thymine were considered unmethylated. Only bases with Phred-scaled quality score of ≥20 were considered. In addition, the 5 bp at the two ends of the reads were excluded from methylation calling according to M-bias plot quality control. For the TWGBS libraries, the first 9 bp of the second read and the last 9 bp before the adaptor of the first read were excluded from methylation calling.

Calling of differentially-methylated regions (DMRs) {#S20}
---------------------------------------------------

The raw counts of methylated and unmethylated reads for each CpG site from different libraries were merged for each replicate. BSmooth[@R37] was used (default parameters, version 1.2.0) to call differentially methylated regions (DMRs) for all possible ten pairwise tissue-tissue comparisons. Each comparison contained three replicates in each group (3vs3 comparison). To account for possible false positive DMRs reported by BSmooth, due to smoothing in non-informative / low coverage regions, we applied additional filtering procedures. On autosomes we selected for DMRs which had a mean CpG-coverage per DMR greater or equal to five in all six replicates in a particular comparison based on raw read counts. We applied a paired Wilcoxon test on each DMR based on the beta-values of the six replicates. To correct for multiple testing, the resulting p-values have been Benjamini-Hochberg corrected and only DMRs with a p-value lower or equal 0.05 were selected. Due to the fact that all animals in this study were male mice, we expected lower coverage for the sex chromosomes. On allosomes, we pooled the raw counts from the three replicates in each group and selected DMRs with a coverage of \>10. All DMRs from all chromosomes were filtered requiring a minimal mean methylation value difference of 0.3.

Principal Component Analysis (PCA) and hierarchical clustering on DMRs {#S21}
----------------------------------------------------------------------

The methylation values of called DMRs from all ten possible tissue-tissue comparisons were joined into a single matrix. Duplicate DMRs (exact same start and end bp position) were eliminated from the matrix. A PCA on all replicates using R (3.1.2) and prcomp was performed. A complete-linkage clustering was performed allowing for clustering of rows (DMRs) and columns (replicates) using R (3.1.2) and pheatmap.

Identification of promoter, intragenic, intergenic regions and TSS {#S22}
------------------------------------------------------------------

Unique DMRs from all ten comparisons have been annotated (bedtools-2.24.0 closest[@R38]) using parameters -d to report distance and -t "first" to handle ties. We used *RefSeq* September 2013 version and defined promoters as 2000 bp upstream if the gene is located on the plus strand and 500 downstream if located on minus strand. The TSS was defined as the first bp downstream if on plus strand and the first bp upstream if on minus strand. Whole-genome data were visualized in a circos plot as described in[@R39].

Calculation of average distance of DMRs from TSS {#S23}
------------------------------------------------

To calculate the distance of DMRs from the transcription start site (TSS), we first normalized all DMRs to the same DNA strand, subtracted the mean DMR genomic localization from the TSS coordinates, grouped the results into 500 bp clusters from -10000 to +10000 bp, and quantified the number of DMRs in each cluster. DMRs with more than 10,000 bp distance from the respective TSS were disregarded.

Pearson Correlation between gene expression and methylation {#S24}
-----------------------------------------------------------

For this analysis, we included DMRs, which were intragenic or within 5kb up/downstream of the nearest gene according to RefSeq annotation. Methylation values and RPKM values were associated with each other using the RefSeq gene identifiers. For each gene we applied a correlation test using Pearson correlation with a cutoff of less or equal -0.7 or greater/equal 0.7 allowing for negative as well as positive correlation.

Hierarchical clustering of DMRs and RNA data {#S25}
--------------------------------------------

From the DMRs with an absolute Pearson correlation coefficient of bigger or equal 0.7, we created a new matrix of methylation values including all replicates. We applied complete-linkage hierarchical clustering to generate a heatmap using R (v3.1.2) and pheatmap. We further applied R (v3.1.2) and mclust(v5.1)\[1\] to estimate the number of clusters using parameters: mclust(..., G=1:20). The resulting number of clusters was four and we cut the resulting tree for the DMRs from the complete-linkage using cutree (..., k=4) into four different clusters.

Motif analysis {#S26}
--------------

For each of the four identified clusters we merged overlapping DMRs (bedtools-2.24.0 merge) to avoid possible bias by overrepresentation and extracted the corresponding genomic DNA sequences (bedtools-2.24.0 fasta). All genomic regions in the four clusters where scored with the JASPAR motif library[@R40] using the total binding affinity (TBA) score. Briefly, the TBA score is computed for each genomic region by summing for each position the maximum PWM score between the plus and minus strand[@R41]. Then, for each PWM, the regions were ranked according to their TBA score in decreasing order. For each PWM, we determined the recovery curve for the regions in a specific cluster, and the area under the curve (AUC) was computed over the first 300 regions. AUC values were converted into a z-score by computing the mean and standard deviation of the AUC over 1000 randomizations of the ranks. For each set of regions inside a cluster, the z-scores for the PWMs were represented as a heatmap. Only motifs which have an absolute z-score above 3 in one of the clusters are displayed.

Mapping of RNA sequencing data, statistical evaluation and plotting {#S27}
-------------------------------------------------------------------

For all samples, low quality bases were removed with Fastq_quality_filter from the FASTX Toolkit 0.0.13 (<http://hannonlab.cshl.edu/fastx_toolkit/index.html>) with 90 percent of the read needing a quality phred score \> 20. Homertools 4.7[@R42] were used for PolyA-tail trimming, and reads with a length \< 17 were removed. PicardTools 1.78 (<https://broadinstitute.github.io/picard/>) were used to compute the quality metrics with CollectRNASeqMetrics. With STAR 2.3[@R43], the filtered reads were mapped against mouse genome 38 using default parameters. Count data were generated using *HTSeq*[@R44] for the genes. For the comparison with DESeq2[@R45], the input tables containing the replicates for groups to compare were created by a custom perl script. For *DESeq2*, *DESeqDataSetFromMatrix* was applied, followed by *estimateSizeFactors*, *estimateDispersions*, and *nbinomWald testing*. The result tables were annotated with gene information (gene symbol, gene type) derived from the gencode.vM8.gtf file. For the RPKM table of non-coding RNAs, a custom perl script separated non-coding RNA genes from protein coding genes and calculated their RPKM values from the *HTSeq* count values. Mapping filtered reads against protein coding transcripts using a custom pipeline generated the RPKM table of the protein coding genes. These genes (status "KNOWN") were extracted from the Mouse EnsEMBL (Rel. 80) database. Mapping was carried out with bowtie2 version 2.2.4[@R46] against union mouse genes: every gene is represented by a union of all its transcripts (exons). The count values (RPKM and raw counts) were calculated by running CoverageBed from Bedtools v2.17.0[@R38] of the mapped reads together with a specific mouse annotation file for protein coding genes (based on Ensembl 80) in gtf format and parsing the output with custom perl scripts. MA plots were generated as described in[@R47]. For hierarchical clustering of RNA data a complete-linkage clustering was performed using R (3.1.2) and pheatmap.

Unsupervised clustering, computing of heatmaps, methylation plotter {#S28}
-------------------------------------------------------------------

Unsupervised hierarchical clustering was performed with Gene Pattern software/hierarchical clustering tool (<http://genepattern.broadinstitute.org/>). Column and row distance measure were set to Pearson correlation with pair-wise average linkage clustering. No normalizations or transformations have been performed. Heatmaps were generated with gene pattern software/heatmap viewer. Methylation plots ([Figure 3C](#F3){ref-type="fig"}, [Supplementary Figure 13c](#SD2){ref-type="supplementary-material"}) were generated with methylation plotter[@R48].

Isolation of RNA and reverse transcription followed by qPCR {#S29}
-----------------------------------------------------------

Sorted cell populations were lysed and RNA was isolated using the RNeasy Mini Kit (Quiagen). Synthesis of cDNA was performed with SuperScript Reverse Transcriptase II and oligo(dT) primers (both Life Technologies) according to manufacturer's instructions. Real-time PCR was performed using a ViiA7 instrument (Applied Biosystems) and Taqman master mix (Applied Biosystems). Gene expression values were normalized to housekeeping genes (*Hprt*).

Purification and bisulfite conversion of genomic DNA {#S30}
----------------------------------------------------

Sorted cell populations were resuspended in PBS and genomic DNA was purified according to manufacturers guidelines using the DNEasy Blood and Tissue kit (Quiagen). For pT~reg~ and tT~reg~ isolation, cells were fixed and stained with the Foxp3 Fix/perm buffer set (eBiosciences) according to manufacturer's instruction. Cells were then sorted into lysis buffer included in the QIAamp DNA micro kit (Quiagen). Reverse cross-linking of gDNA was performed for one hour at 56°C and one hour at 90°C, followed by gDNA isolation. DNA purity and concentration was measured with a NanoDrop or Qubit photometer. Bisulfite-conversion was performed using the EpiTect Bisulfite Conversion Kit (Quiagen) and converted DNA was used immediately after purification or aliquoted and stored at -20°C.

Computation and testing of bisulfite-DNA primers {#S31}
------------------------------------------------

Genomic DNA was *in-silico* bisulfite-converted using the Bisulfite Primer Seeker software (<http://www.zymoresearch.com/tools/bisulfite-primer-seeker>). Primer sequences were calculated based on manufacturers recommendations. Primer pairs were tested on bisulfite-converted genomic DNA to determine optimal annealing temperature range and cycle number for each specific reaction. Once parameters were optimized, adaptor sequences for 454 sequencing and barcodes to distinguish individual samples were attached to each primer pair sequence and synthesized. Alternatively, Illumina adapter sequences were attached to primer pairs for Illumina sequencing. Based on optimal annealing temperature and PCR cycle number, primers were used to generate PCR amplicons from bisulfite-converted DNA for each cell type tested. An overview of primers used for our sequencing experiments is listed in the key resources table. Once genomic DNA had been bisulfite-converted, PCR reactions with bisulfite-specific primers were performed. PCR amplicons were separated from primer dimers on 1%-2% agarose gels and visualized using ethidium bromide. Specific bands were excised under UV light exposure and DNA amplicons were purified using a Quick Gel Extraction Kit (Life Technologies). Equimolar amounts of amplicons were combined and processed on a GS Junior Sequencer (Roche). Sequence reads were aligned to the bisulfite-converted mouse genome and methylation levels were visualized in heat maps. Alternatively, Illumina-tagged amplicons were processed on an Illumina MiSeq V3 machine with Paired-End 300bp or Paired-End 250bp settings. Raw data were aligned to the mouse genome and CpG methylation was calculated. Detailed genomic positions of amplicon data are either labeled in the respective graph or depicted here: *Foxp3* R3 ([Figure 3g](#F3){ref-type="fig"}; CG\#1: 7,583,950; CG\#2: 7,583,986; CG\#3: 7,584,002; CG\#4: 7,584,036; CG\#5: 7,584,063; CG\#6: 7,583,950), *Ikzf2* ([Figure 3g](#F3){ref-type="fig"}; CG\#1: 69,670,284; CG\#2: 69,670,291; CG\#3: 69,670,370; CG\#4: 69,670,377; CG\#5: 69,670,385), *Il2ra* ([Figure 3g](#F3){ref-type="fig"}; CG\#1: 11,645,653; CG\#2: 11,645,705; CG\#3: 11,645,718; CG\#4: 11,645,738), *Ctla4* ([Figure 3g](#F3){ref-type="fig"}; CG\#1: 60,912,472; CG\#2: 60,912,521; CG\#3: 60,912,536; CG\#4: 60,912,573), *Gata3* ([Figure 7f](#F7){ref-type="fig"}; CG\#1: 9,868,708; CG\#2: 9,868,720; CG\#3: 9,868,768; CG\#4: 9,868,789; CG\#5: 9,868,820; CG\#6: 9,868,844; CG\#7: 9,868,855; CG\#8: 9,868,858; CG\#9: 9,868,883; CG\#10: 9,868,948; CG\#12: 9,868,958), *Lef1* ([Figure 7f](#F7){ref-type="fig"}; CG\#1: 131,116,109; CG\#2: 131,116,113; CG\#3: 131,116,152; CG\#4: 131,116,173; CG\#5: 131,116,187; CG\#6: 131,116,191; CG\#7: 131,116,196; CG\#8: 131,116,257; CG\#9: 131,116,288; CG\#10: 131,116,302; CG\#11: 131,116,327, CG\#12: 131,116,356).

Flow cytometry {#S32}
--------------

Tissues were isolated and digested as described previously. Single-cell suspension were stained with surface antibodies for 30 minutes at 4°C. If applicable, cells were fixed and permeabilized with the Foxp3 Fix/Perm Buffer Set (eBiosciences) for one hour at RT, followed by intracellular staining. Antibodies used for flow cytometry experiments were conjugated to either Brilliant Violet 411, eFluor 506, Brilliant Violet 605, Brilliant Violet 711, Brilliant UV 395, Brilliant UV 737, PE, AF488/FITC, PE-Cy7, AF647/APC, APC-Cy7, or PerCP-Cy5.5 and are listed in key resources table. Following life dead exclusion dyes were used: Fixable viability dye eFluor506 and eFluor780 (eBiosciences). If applicable, biotin-labeled primary antibodies were stained with fluorchrome-labeled secondary antibodies for 30 minutes at 4°C. Primary Lef1 and Tcf7 antibodies were stained with an anti-rabbit-IgG AF 647-conjugated secondary antibody. Areg and IL-10 stainings were performed as intracellular staining. Samples were acquired on a BD LSRII or a LSR Fortessa 5-laser flow cytometer. Biological replicates were measured separately. Data were analyzed with FlowJo software, and, in figures, concatenated files of biological replicates are shown. Concatenation was performed with FCS Concat (Cytobank).

IL-4 co-culture of T~reg~ cells; iT~reg~ cell induction {#S33}
-------------------------------------------------------

Spleen and lymph nodes from Foxp3.IRES-DTR/GFP animals were harvested. T~reg~ cells were pre-enriched with CD25 bead-based positive selection, while T~conv~ cells were pre-enriched with CD4 bead-based positive selection (autoMACS Pro Separator, Miltenyi Biotec). Pre-enriched T~reg~ and T~conv~ cells were sorted by FACS to isolate pure KLRG1^--^ST2^--^ populations from both cell types. Cells were then seeded at 100,000 cells per well with anti-CD3/CD28 beads (Life technologies), IL-12-23p40 blocking mAb, IFNγ blocking mAb, murine IL-2 (Peprotech) and escalating doses of murine IL-4 (Peprotech). Cells were incubated for six days at 37°C and afterwards lysed for immediate RNA isolation, cDNA synthesis and real-time PCR, as described previously.

To generate *in vitro* induced T~reg~ cells (iT~reg~ cells), T~conv~ cells were pre-enriched by negative selection with CD8, CD11b, CD11c, CD19, CD25, and CD49b antibodies and magnetic beads. Afterwards, cells were treated with murine TGF-β (Peprotech) and incubated with CD3/28 microbeads for six days at 37°C.

Measurement of IL-10 and AREG production in spleen T cells {#S34}
----------------------------------------------------------

Spleens from Foxp3.IRES-DTR/GFP animals were harvested. Single-cell suspensions were established and red blood cells lysed. Afterwards, cells were treated with 1X PMA and Ionomycin cell stimulation cocktail plus transport inhibitor (eBiosciences) or 1X transport inhibitor only. In addition, all samples were subjected to metalloproteinase inhibitor treatment with 10 µM Marimastat (Sigma). Cells were stimulated for 4 hours at 37°C, followed by surface staining, fixation with the Foxp3 Fix/Perm Buffer Set (eBiosciences), and subsequent measurement via flow cytometry.

Single-cell RNA sequencing {#S35}
--------------------------

To generate the single-cell RNA-sequencing (scRNA-seq) data, we isolated tisT~reg~ST2 from pooled spleens, followed by cell capture, cDNA synthesis and amplification on the C1 Single-Cell Auto Prep IFC (Fluidigm). In two separate runs, a total of 127 cells corresponded to single cells (as confirmed by visual inspection of the captured cells). Sequencing libraries were produced with the Illumina Nextera XT kit according to an adopted Fluidigm protocol. All single cells from one C1 run (about 65 cells on average) were pooled and sequenced 1x50 bp reads on an Illumina HiSeq 2000 machine. For each cell, reads were aligned to the murine genome (ERCC sequences concatenated to GRCm38.p4 version 84) with STAR[@R43] version 2.5. On average 70 % of the reads were uniquely mapped. Raw counts were quantified from position-sorted alignment files with HTSeq-count[@R44] using mode \'union\' and default quality thresholds of 10. In order to remove bias introduced by low quality data we performed the quality control using the scater package as described in[@R49]. Cells were removed as low quality if one or more of the following conditions were met: low library size (0 cells), low number of captured transcripts (2 cells), exceeding mitochondrial content (11 cells) or exceeding ERCC sequences (13 cells). In total 101 cells remained for further analysis. The scran package[@R49] was used to normalize raw counts with deconvolution and to identify HVGs, (with ERCC-fit, span=0.2, FDR=0.05).

Stability of tisT~reg~ST2 *in vitro* {#S36}
------------------------------------

KLRG1^+^ST2^+^ tisTregST2 from fat were isolated by FACS as described previously. In addition, KLRG1-ST2- T~reg~ from spleen were isolated by FACS. Samples were frozen for 0h timepoint analysis or tisT~reg~ST2 and KLRG1-ST2- cells were incubated with CD3/CD28 microbeads (Dynabeads, Thermo Fisher Scientific) and 5000 U/mL IL-2 for six days at 37°C. Then, cells were lysed and RNA was isolated. Gene expression was determined by qPCR with Taqman probes as described previously. Four biological replicates have been performed.

Transfer of congenically-labeled KLRG1^--^ST2^--^ T~reg~ cells into T~reg~-depleted hosts {#S37}
-----------------------------------------------------------------------------------------

T~reg~ cells were isolated from CD45.2^+^ Foxp3^YFP,\ Cre^ animals with CD25 bead-based pre-enrichment and a reduced staining protocol (CD8^--^CD19^--^CD25^+^Foxp3-YFP^+^KLRG1^--^ST2^--^). Cells were then injected into CD45.1^+^ recipient animals intravenously. Control animals received PBS injections. In addition, all recipient animals were treated with peritoneal injections of Diptheria Toxin (DT) to eliminate all host-resident T~reg~ cells. DT injections were repeated after 24 hours. Animals were analyzed ten days after T~reg~/PBS injections have been performed. Four recipient animals were treated with T~reg~ injections from five donor animals. Four recipients were treated with PBS injections. Two animals were used as untreated controls to ensure proper gating.

Expansion of tisT~reg~ST2 with IL-33 *in vitro* {#S38}
-----------------------------------------------

Foxp3^GFP^ animals were injected with either 5μg recombinant murine IL-33 or PBS into the peritoneum on day 1 and day 3 (Biolegend). On day six, mice were sacrificed and frequency and percentage of tisT~reg~ST2 in tissues was evaluated by flow cytometry.

Bioinformatics and statistical analysis {#S39}
---------------------------------------

Massive parallel sequencing data were statistically tested as described above, and these statistical values were used in [Fig. 2a](#F2){ref-type="fig"} (MA plots), 5c (*Pparg*), 5d (*Gpr55*), 6b (*Irf4*, *Rora*, *Batf*), 6d (*Il10*), and [Supplementary Fig. 12, 13a, 13b, 15a, 15b and 20](#SD2){ref-type="supplementary-material"} with n=3 for all comparisons. Data based on flow cytometry or real-time PCR were tested with unpaired two-tailed student's t tests in [Fig. 6e](#F6){ref-type="fig"} (n=4), 7c (n=10), 7d+g (n=4), 8d (n=6-10), 8e (n=4) and in [Supplementary Fig. 18a](#SD2){ref-type="supplementary-material"} (n=10), 19a (n=4), 19b (n=4), 21b (n=5), 21c (n=4). One-way ANOVA with Bonferoni post-test was used in [Figures 5a](#F5){ref-type="fig"} (n=4-19), 5d (CD103, n=9), 6b (GATA-3, n=4-19), 6d (ST2, n=4), and [Supplementary Fig. 13c](#SD2){ref-type="supplementary-material"} (n=4-19), 14b (n=6-7), 16c (n=4-19), 17b (n=4), 19c (n=8). Dunnett posttest to compare all columns vs. control column was utilized in [Supplementary Fig. 14a](#SD2){ref-type="supplementary-material"} (n=4). All graphs represent the mean of at least three biological replicates ± Standard Deviation (SD). Statistical significance is indicated by asterisks: \*\*\*=p\<0.001; \*\*=p\<0.01; \*=p\<0.05. To identify the T~H~2 bias of tissue T~reg~ cells, we used a dataset derived from *in vitro* differentiated T~H~1, T~H~2, T~H~17, and iT~reg~ cells[@R16]. Genes specifically up- or down-regulated in T~H~2 polarized cells were identified in the comparisons: T~H~2 vs. T~H~1, T~H~2 vs. T~H~17, and T~H~2 vs. naïve T cells. T~H~2-specific genes had to be differential in all three comparisons (\>2-fold). We plotted both T~H~2-specific gene lists (up and down) on our gene expression dataset (Fat T~reg~ vs. LN T~reg~ and Skin T~reg~ vs. LN T~reg~). The significance of bias was evaluated by chi square testing.

Data availability {#S40}
-----------------

Fastq files from TWGBS, RNA-Seq, and single-cell RNA-Seq that support the findings of this study have been deposited in European Nucleotide Archive (ENA) with the accession code PRJEB14591 (<http://www.ebi.ac.uk/ena/data/view/PRJEB14591>).
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![DNA methylome analysis of tissue-resident T~reg~ cells.\
**(a)** Circos plot illustrating tagmentation-based whole-genome bisulfite sequencing (TWGBS) methylation data for chromosomes 1-19 and sex chromosomes X and Y for fat, skin, liver, and LN T~reg~ cells and LN T~conv~ cells. Cumulated methylation values are shown in brackets. Color codes indicate mean methylation and mean methylation difference, respectively. (**b**) Unsupervised hierarchical cluster of 11,744 differentially methylated regions (DMRs) identified via TWGBS of fat, skin, liver, and LN T~reg~ cells and LN T~conv~ cells. DMRs were identified as at least 30% differentially methylated in pairwise comparisons. Three replicates per group are shown, with numbers indicating the respective replicate. Colors indicate low (yellow) or high (blue) DMR methylation. (**c**) Group-wise comparison of DMRs and stratification of DMRs into promoter-resident, intragenic or intergenic based on their genomic location, as shown in more detail in [Supplementary Fig. 2d](#SD2){ref-type="supplementary-material"}. Numbers are derived from pairwise comparisons of indicated groups. (**d**) Average distance of DMRs from the transcription start site (TSS) of the closest gene. (**e**) Principal Component Analysis (PCA) of the different groups based on DMR methylation. Three replicates per group are shown. Colors indicate cell type, with LN T~reg~ (yellow), LN T~conv~ (green), liver T~reg~ (black), fat T~reg~ (purple) and skin T~reg~ (blue).](emss-73219-f001){#F1}

![Transcriptome analysis of tissue-resident T~reg~ cells and correlation with epigenetic dataset.\
(**a**) MA plots calculated from RNA sequencing data of fat vs. LN T~reg~, skin T~reg~ vs. LN T~reg~ cells, fat vs. skin T~reg~, and LN T~reg~ vs. T~conv~ cells. Numerators are plotted as mean of normalized counts. Fold changes are presented as log2. Significantly up- or downregulated genes (p\<0.05) are highlighted in red, with the respective numbers shown above or below. Selected genes are labeled. (**b**) Unsupervised hierarchical clustering of gene expression data. Three replicates per group are shown, with numbers indicating the respective replicate. (**c**) Unsupervised hierarchical clustering of DMR methylation data. Three replicates per group are shown. (**d**) Pearson correlation between gene expression and DMR methylation. DMRs were intragenic or within 5kb of the nearest gene. Red line represents the median.](emss-73219-f002){#F2}

![Methylation changes of T~reg~-specific epigenetic signature.\
(**a**) Methylation mean difference (LN T~reg~ -- LN T~conv~) and corresponding log2 RNA expression for promoter and intragenic DMRs identified between LN T~reg~ and T~conv~ cells. Selected demethylated and upregulated genes are highlighted in red, hypermethylated and downregulated genes in blue. Linear regression line in grey. (**b**) Methylation profile of LN T~reg~ (orange line), LN T~conv~ (green line), Fat T~reg~ (purple line), Skin T~reg~ (blue line) and Liver T~reg~ (grey line) for known T~reg~ function-related genes *Foxp3*, *Ctla4*, *Ikzf2*, *Ikzf4*, *Il2ra*, and *Il2rb*. Each line represents average methylation values derived from three individual replicates. Little ticks at the bottom of each plot represent location of individual CpGs. Arrows indicate gene direction, black bars gene body regions, red bars annotated promoter regions, blue bars exons. Methylation levels are beta values ranging from 0 (unmethylated) to 1 (methylated). (**c**) Detailed analysis of the *Foxp3* gene with superimposed annotation of introns and exons as well as promoter region (PRO) and conserved non-coding regions 1-3 (CNS). Each circle represents one CpG and the color-code represents degree of methylation from yellow (low) to blue (high). Areas R1-R3 labeled in red represent regions for amplicon-based validation via bisulfite sequencing. (**d-g**) PCR amplicon sequencing of bisulfite-converted genomic DNA. Thymic T~reg~ and T~reg~ precursor cells (**d**), LN T~reg~, T~conv~ cells and *in vitro* induced T~reg~ cells (iT~reg~) (**e**), tissue-isolated T~reg~ cells (**f**), and spleen-derived pT~reg~ cells, spleen-derived tT~reg~ cells and splenic Tconv cells (**g**). Yellow represents unmethylated and blue methylated CpG, while numbers depict quantity of analyzed reads.](emss-73219-f003){#F3}

![Identification of epigenetic and transcriptional changes in tissue-resident T~reg~ cells.\
(**a**) Methylation mean difference and corresponding log2 RNA expression plot as described in [Fig. 3a](#F3){ref-type="fig"} for DMRs identified in the comparison fat T~reg~ vs. LN T~reg~ (upper panel) and skin T~reg~ vs. LN T~reg~ (lower panel). (**b**) Heatmaps of candidates (106 genes) for DMR methylation (left) and gene expression (middle) shown for skin, fat and LN T~reg~ cells. Right panel, gene expression of candidate genes in T~conv~ cells isolated from LN, skin and fat. T~reg~ and T~conv~ gene expression data were row-normalized together. Color codes indicate high (blue) or low (yellow) methylation (left panel) or high (red) and low (blue) gene expression (right panel). (**c**) Methylation profiles of indicated genes from (**b**) are plotted. Plots are as described in [Fig. 3b](#F3){ref-type="fig"}. Each line represents average methylation values derived from three individual replicates. Plotted are skin (blue), fat (purple), and LN T~reg~ (yellow) and LN T~conv~ (green).](emss-73219-f004){#F4}

![Validation of the common tissue T~reg~ signature and identification of tissue-specific patterns.\
(**a**) Flow cytometry analysis of TIGIT, KLRG1, ST2, BCL-2, TCF7 and LEF1 in fat, skin and LN T~reg~ cells (CD19^--^MHCII^--^CD3^+^CD8^--^CD4^+^CD25^+^Foxp3^+^) and corresponding T~conv~ cells (CD19^--^MHCII^--^CD3^+^CD8^--^CD4^+^CD25^--^ Foxp3^--^). Contour plots are concatenated files representative of four replicates, quantification at bottom part. Individual mice are shown (n=4). Statistical evaluation based on one-way ANOVA with Bonferoni post-test (\*\*\*=p\<0.001). (**b**) Differences in DMR methylation and gene expression of the comparison T~reg~ cells from fat vs. skin as described in [Fig. 3a](#F3){ref-type="fig"}. (**c**) Methylation pattern of the gene *Pparg* and corresponding gene expression. Shown are skin (blue), fat (purple), and LN T~reg~ (yellow). Each line represents one individual replicate (n=3). Gene expression is plotted as reads per kilobase per million mapped reads (Rpkm). Significance based on RNA sequencing calculations as described in methods section and indicated by asterisks. (**d**) Methylation of *Itgae* (CD103) and *Gpr55* in skin (blue), fat (purple), and LN T~reg~ (yellow) as in (**c**). Quantification of CD103 data are based on (**e**), where contour plots indicate CD103 expression on T~reg~ cells from LN, fat and skin measured via flow cytometry. Statistical evaluation based on one-way ANOVA with Bonferoni post-test (n=9). Means are shown with standard deviation (SD)](emss-73219-f005){#F5}

![Fat and skin T~reg~ cells are T~H~2-like polarized.\
(**a**) Gene Ontology (GO) term analysis of the gene list described in [Fig. 4b](#F4){ref-type="fig"}. (**b**) Methylation profile and protein (GATA-3) or gene expression for *Gata3*, *Irf4*, *Rora* and *Batf* as described in [Fig. 3b](#F3){ref-type="fig"}. Average methylation values derived from three individual replicates are shown for fat T~reg~ (purple), skin T~reg~ (blue), LN T~reg~ (yellow) and LN T~conv~ (green). (**c**) Diagnostic T~H~2 up- (red, left panel) or downregulated (blue, right panel) signature genes are plotted for the comparison skin vs. LN T~reg~ (upper panel) and fat vs. LN T~reg~ (lower panel). Numbers indicate the number of genes per site. Individual genes are highlighted. Chi2-test for proportions. (**d**) Methylation profile and protein or gene expression of *Il1rl1* and *Il10* as described in (**b**). ST2 expression quantification based on [Fig. 5a](#F5){ref-type="fig"} and statistically evaluated with one-way ANOVA (n=4). (**e**) Culture of T~reg~ or T~conv~ cells with 25 ng/mL IL-4 (+) or control (-) followed by qPCR-based evaluation of target gene expression. Statistical evaluation with unpaired two-tailed student's t test (n=4). (**f**) Tissue T~reg~ methylation data were grouped into 4 specific methylation-expression clusters (top panel). Based on these clusters, binding motif enriched factors were calculated and illustrated in a heat map (middle panel). Gene expression values of cluster 2 binding motif enriched factors for fat T~reg~, skin T~reg~, liver T~reg~, LN T~conv~ and LN T~reg~ are shown as heatmap (bottom panel), where colors indicate relative expression (high=red; low=blue). Individual replicates are shown (n=3). Means are shown with SD.](emss-73219-f006){#F6}

![Identification of tisT~reg~ST2 cells.\
(**a**) TisT~reg~ST2 cells (CD8^--^CD19^--^MHCII^--^CD3^+^CD4^+^CD25^+^Foxp3^+^ST2^+^KLRG1^+^GATA-3^+^) population (R1) and identification of this population in different tissues. KLRG1^--^ST2^--^ T~reg~ cells served as controls (R2). Contour plots and histograms are based on concatenated files of four or more biological replicates. (**b**) Quantification of tisT~reg~ST2 frequency in different tissues. (**c**) Frequency distribution of tisT~reg~ST2 in pT~reg~ and tT~reg~ population in the colon. pT~reg~ cells were defined as CD8^--^CD19^--^MHCII^--^CD4^+^CD25^+^Foxp3^+^HELIOS^--^RORγt^+^, and tT~reg~ were defined as CD8^--^CD19^--^MHCII^--^CD4^+^CD25^+^Foxp3^+^HELIOS^+^RORγt^--^. tisT~reg~ST2 were identified as KLRG1^+^ST2^+^ of the respective T~reg~ type. Statistical evaluation with two-tailed unpaired student's t test (n=10). (**d**) Spleen cells were stimulated as described. TisT~reg~ST2 cells were identified as CD45^+^TCRβ^+^CD4^+^CD8^--^Foxp3^+^KLRG1^+^ST2^+^ cells (R2, red) and stained for intracellular expression of AREG and IL-10. KLRG1^--^ST2^--^ T~reg~ cells (R1, blue) were used as control. Right panel, quantification. Statistical evaluation with one-way ANOVA and Bonferoni post-test (n=4). Additional controls shown in [Supplementary Fig. 19](#SD2){ref-type="supplementary-material"}. (**e**) TisT~reg~ST2 from spleen (tisT~reg~ST2 Spl) and ST2^--^KLRG1^--^ T~reg~ cells (T~reg~ Spl) from spleen were isolated using FACS and expression of different genes was analyzed via qPCR. Color code depicts gene expression value (red=high, blue=low). (**f**) Methylation of CG dinucleotides at the *Gata3*, *Klrg1* and *Lef1* DMR locus is shown for indicated groups, with blue indicating high and yellow indicating low methylation levels. (**g**) Expression of *Grp55* and *Pparg*, based on the gene expression dataset derived from (**e**). (**h**) scRNASeq analysis of 101 tisT~reg~ST2 cells derived from spleen. Gene expression of tisT~reg~ST2-associated markers *Helios, Gata3, Klrg1, Tigit*, and skin associated marker *Itgae, Ahr and Gpr55*. t-SNE analysis of single tisT~reg~ST2 cells with a skin T~reg~ signature. Expression of *Ahr* is indicated by dot size. Means are shown with SD.](emss-73219-f007){#F7}

![Characterization of the tisT~reg~ST2 population.\
(**a**) Frequency of tisT~reg~ST2 in mice. Data are derived from fat, skin, lymph nodes and spleen from mice of 5, 10, 15, 20, and 25 weeks of age. TisT~reg~ST2 were gated as described in [Fig. 7](#F7){ref-type="fig"}. Additional plots are shown in [Supplementary Fig. 21](#SD2){ref-type="supplementary-material"}. Contour plots are concatenated files representative of five replicates. (**b**) CD45.2^+^KLRG1^--^ST2^--^ T~reg~ cells were isolated from CD45.2^+^ Foxp3^Cre,YFP^ donor animals and injected into DT-treated CD45.1^+^ Foxp3^GFP,DTR^ recipients. After ten days, presence of tisT~reg~ST2 was evaluated by flow cytometry. Contour plots are representative examples of four replicates. (**c**) Gene-expression analysis of *in vitro* cultivated and activated tisT~reg~ST2 (fat) and KLRG1^--^ST2^--^ (spleen) T~reg~ cells. Cultivated for six days with anti-CD3 and anti-CD28 microbeads and IL-2. Gene expression of tisT~reg~ST2 genes was measured by qPCR. Colors indicate gene expression levels with red=high and blue=low relative expression. (**d**) Flow cytometry anaylsis of T~reg~ cells in tissues of Batf-deficient mice (Batf^--/--^) versus Batf-sufficient wildtype mice (Batf^+/+^). Dot plots are concatenated files representative of six to ten replicates. Individual mice are shown. Statistical evaluation based on two-tailed unpaired student's t test (n=6-10). (**e**) Flow cytometry analysis of T~reg~ cells in tissues of wildtype mice treated with of IL-33 or PBS. Dot plots are concatenated files representative of four replicates. Additional plots are shown in [Supplementary Fig. 21](#SD2){ref-type="supplementary-material"}. Individual mice are shown. Statistical evaluation based on two-tailed unpaired student's t test (n=4). Means are shown with SD.](emss-73219-f008){#F8}
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  eFluro450 Streptavidin                                                 Affymetrix eBioscience     Cat\# 48-4317-82
  FITC Streptavidin                                                      Biolegend                  Cat\# 405201
  PE Streptavidin                                                        Biolegend                  Cat\# 405204
  PE/Cy7 Streptavidin                                                    Biolegend                  Cat\# 405206
  PerCP/Cy5.5 Streptavidin                                               Biolegend                  Cat\# 405214
  Brilliant UV 395 Streptavidin                                          BD Biosciences             Cat\# 564176
  Brilliant UV 737 Streptavidin                                          BD Biosciences             Cat\# 564293
  APC Streptavidin                                                       Biolegend                  Cat\# 405207
  Brilliant Violet 421 Streptavidin                                      Biolegend                  Cat\# 504421
  Brilliant Violet 421 Streptavidin                                      Biolegend                  Cat\# 504421
                                                                                                    
  **Primers & Probes**                                                                              
  Taqman Probe for *Hprt*                                                Thermo Fisher              Mm01318746_g1
  Taqman Probe for *Il2ra*                                               Thermo Fisher              Mm01340213_m1
  Taqman Probe for *Foxp3*                                               Thermo Fisher              Mm00475162_m1
  Taqman Probe for *Il7r*                                                Thermo Fisher              Mm00434295_m1
  Taqman Probe for *Pparg*                                               Thermo Fisher              Mm01184322_m1
  Taqman Probe for *Tbx21*                                               Thermo Fisher              Mm00450960_m1
  Taqman Probe for *Irf4*                                                Thermo Fisher              Mm00516431_m1
  Taqman Probe for *Gata3*                                               Thermo Fisher              Mm00484683_m1
  Taqman Probe for *Il10*                                                Thermo Fisher              Mm01288386_m1
  Taqman Probe for *Il1rl1*                                              Thermo Fisher              Mm00516117_m1
  Taqman Probe for *Rora*                                                Thermo Fisher              Mm01173766_m1
  Taqman Probe for *Areg*                                                Thermo Fisher              Mm00452865_m1
  Taqman Probe for *Osbpl3*                                              Thermo Fisher              Mm00452865_m1
  Taqman Probe for *Tcf7*                                                Thermo Fisher              Mm00493445_m1
  Taqman Probe for *Lef1*                                                Thermo Fisher              Mm00550265_m1
  Taqman Probe for *Lmna*                                                Thermo Fisher              Mm00497783_m1
  Taqman Probe for *Ms4a4b*                                              Thermo Fisher              Mm00649916_m1
  Taqman Probe for *Klrg1*                                               Thermo Fisher              Mm00516879_m1
  Taqman Probe for *Tigit*                                               Thermo Fisher              Mm03807522_m1
  Taqman Probe for *Foxp1*                                               Thermo Fisher              Mm00474848_m1
  Taqman Probe for *Batf*                                                Thermo Fisher              Mm00479410_m1
  Taqman Probe for *Grp55*                                               Thermo Fisher              Mm02621622_s1
  Bisulfite-DNA primer for *Foxp3* Upstream R1                           Forward Primer             AGGATGTTAGGGTATTAAAGGTTGG
  Bisulfite-DNA primer for *Foxp3* Upstream R1                           Reverse Primer             CCAATTTTCCTAAAACCAACAATAT
  Bisulfite-DNA primer for *Foxp3* R2 (R2.1)                             Forward Primer             AGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTG
  Bisulfite-DNA primer for *Foxp3* R2 (R2.1)                             Forward Primer             TCTTACRTAACACAAACAAAAAATCAATTAAATAC
  Bisulfite-DNA primer for *Foxp3* R2 (R2.2)                             Reverse Primer             GTTGTGGTATTGTGTTTGGTATATG
  Bisulfite-DNA primer for *Foxp3* R2 (R2.2)                             Forward Primer             ACACTTAATTCAAATAATCAAATTCATAAT
  Bisulfite-DNA primer for *Foxp3* R3 (TSDR)                             Reverse Primer             TGGGTTTTTTTGGTATTTAAGAAAG
  Bisulfite-DNA primer for *Foxp3* R3 (TSDR)                             Forward Primer             AAAAAACAAATAATCTACCCCACAA
  Bisulfite-DNA primer for *Foxp3* R4 (Exon 8)                           Forward Primer             TGAAAGGTTATAATGAAATGATAAGTTTAA
  Bisulfite-DNA primer for *Foxp3* R4 (Exon 8)                           Forward Primer             ATTACCATAACTTCCCCAAAAATAC
  Bisulfite-DNA primer for *Foxp3* R5 (Exon 11)                          Forward Primer             TGATTGTTAATTTTGTTTTTGATTG
  Bisulfite-DNA primer for *Foxp3* R5 (Exon 11)                          Reverse Primer             CAACCTCAATCTCATAATTTTAACC
  Bisulfite-DNA primer for *Gata3* DMR                                   Forward Primer             AGAAGGGAAGAAAAATAAAGGAGAGAAAATTATTAG
  Bisulfite-DNA primer for *Gata3* DMR                                   Reverse Primer             CCTCCCTCATCATTCTAAATATTACCTC
  Bisulfite-DNA primer for *Klrg1* DMR                                   Forward Primer             GAGTTGGGGTAGTAGAGAGTTTTATTTTG
  Bisulfite-DNA primer for *Klrg1* DMR                                   Reverse Primer             ACTATACCTCATAAATATATACAATCACTATCTCTCC
  Bisulfite-DNA primer for *Lef1* DMR                                    Forward Primer             TTGTTGTTAATTGGGGAAATATTTGAAGTTGTTG
  Bisulfite-DNA primer for *Lef1* DMR                                    Reverse Primer             AACRTAAAACTAAAAACAAACAACTAATTATAACC
  Bisulfite-DNA primer for *Ctla4* Exon 2 (derived from [@R13])          Forward Primer             TGGTGTTGGTTAGTAGTTATGGTGT
  Bisulfite-DNA primer for *Ctla4* Exon 2 (derived from [@R13])          Reverse Primer             AAATTCCACCTTACAAAAATACAATC
  Bisulfite-DNA primer for *Ikzf2* Intron 3a (derived from [@R13])       Forward Primer             AGGATGGTTTTTATTGAAGGTGAT
  Bisulfite-DNA primer for *Ikzf2* Intron 3a (derived from [@R13])       Reverse Primer             ATACACACCAAACAAACACTACACC
  Bisulfite-DNA primer for *Il2ra* Intron 1a (derived from [@R13])       Forward Primer             TTTTAGAGTTAGAAGATAGAAGGTATGGAA
  Bisulfite-DNA primer for *Il2ra* Intron 1a (derived from [@R13])       Reverse Primer             TCCCAATACTTAACAAAACCACATAT
                                                                                                    
  **Critical Chemicals**                                                                            
  Collagenase II                                                         Sigma Aldrich              Cat\# C6885
  Collagenase IV                                                         Sigma Aldrich              Cat\# C5138
  Bovine Serum Albumin BSA                                               Sigma Aldrich              Cat\# A4503
  DNAse                                                                  Roche                      Cat\# 11284932001
  Ez-Tn5 transposase                                                     Epicentre                  Cat\# EZI011RK
  Bst DNA polymerase                                                     New England Biolabs        Cat\# M0275S
  5mC-dNTP mix                                                           Zymo Research              Cat\# D1030
  Power SYBR Green Master Mix                                            Thermo Fisher              Cat\# 4367659
  Taqman Gene Expression Master Mix                                      Thermo Fisher              Cat\# 4359016
  NEBNext Multiplex Oligos for Illumina                                  New England Biolabs        Cat\# E7335, E7500
  NEBNext High Fidelity 2x PCR Master Mix                                New England Biolabs        Cat\# M0541
  SuperScript II Reverse Transcriptase                                   Thermo Fisher Scientific   Cat\# 18064071
  Oligo d(T) 12-18 Primer                                                Thermo Fisher              Cat\# 18418012
  Anti-biotin Microbeads                                                 Miltenyi Biotec            Cat\# 130-090-385
  Dynebeads Mouse T-Activator CD3/CD28                                   Thermo Fisher              Cat\# 11456D
  Anti-Mouse IL-12/IL-23 p40 Functional Grade Purified 500 ug Antibody   Affymetrix eBioscience     [AB_469233](http://antibodyregistry.org/AB_469233)
  Purified anti-mouse IFN-gamma antibody                                 Biolegend                  [AB_315396](http://antibodyregistry.org/AB_315396)
  Recombinant murine IL-2                                                Peprotech                  Cat\# 212-12
  Recombinant murine IL-4                                                Peprotech                  Cat\# 214-14
  Recombinant murine IL-33                                               Biolegend                  Cat\# 580506
  Recombinant human TGF-beta                                             Peprotech                  Cat\# 100-21
  PMA/Ionomycin stim cocktail plus transport inhibitors                  Affymetrix eBioscience     Cat\# 00-4975-03
  Marimastat                                                             Sigma Aldrich              Cat\# M2699
                                                                                                    
  **Critical Commercial Kits**                                                                      
  Quick gDNA Microprep Kit                                               Zymo Research              Cat\# D3020
  RNEasy Mini Kit                                                        Quiagen                    Cat\# 74104
  Ampure Beads                                                           Beckman Coulter            Cat\# A63881
  EZ DNA methylation kit                                                 Zymo Research              Cat\# D5002
  Kapa 2G Robust HotStart ReadyMix                                       Kapa Biosystems            Cat\# KK5701
  Smarter Ultra Low Input RNA                                            Clontech Labs              Cat\# 634888
  NEXT ChIP-Seq Library Prep Master Mix                                  New England Biolabs        Cat\# E6240
  QIAamp DNA micro kit                                                   Quiagen                    Cat\# 56304
  DNEasy Blood and Tissue kit                                            Quiagen                    Cat\# 69504
  EpiTect Bisulfite conversion kit                                       Zymo Research              Cat\# 59104
  PureLink Quick Gel Extraction Kit                                      Thermo Fisher              Cat\# K210012
  Foxp3 / Transcription Factor Staining Buffer Set                       Affymetrix eBioscience     Cat\# 00-5523-00
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